KR100547049B1 - 바이러스 감염증 치료를 위한 조성물 및 방법 - Google Patents

바이러스 감염증 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR100547049B1
KR100547049B1 KR1019997003052A KR19997003052A KR100547049B1 KR 100547049 B1 KR100547049 B1 KR 100547049B1 KR 1019997003052 A KR1019997003052 A KR 1019997003052A KR 19997003052 A KR19997003052 A KR 19997003052A KR 100547049 B1 KR100547049 B1 KR 100547049B1
Authority
KR
South Korea
Prior art keywords
amino acid
acid residue
protein
hiv
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019997003052A
Other languages
English (en)
Korean (ko)
Other versions
KR20000048994A (ko
Inventor
프랭크 비. 겔더
Original Assignee
프로브 인터내쇼날
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로브 인터내쇼날 filed Critical 프로브 인터내쇼날
Priority to KR1020057016920A priority Critical patent/KR100667121B1/ko
Publication of KR20000048994A publication Critical patent/KR20000048994A/ko
Application granted granted Critical
Publication of KR100547049B1 publication Critical patent/KR100547049B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1143—Gag-pol proteins, e.g. p17or p24
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019997003052A 1996-10-10 1997-10-10 바이러스 감염증 치료를 위한 조성물 및 방법 Expired - Lifetime KR100547049B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020057016920A KR100667121B1 (ko) 1996-10-10 1997-10-10 바이러스 감염증 치료를 위한 조성물 및 방법

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2819496P 1996-10-10 1996-10-10
US60/028,194 1996-10-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020057016920A Division KR100667121B1 (ko) 1996-10-10 1997-10-10 바이러스 감염증 치료를 위한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20000048994A KR20000048994A (ko) 2000-07-25
KR100547049B1 true KR100547049B1 (ko) 2006-02-01

Family

ID=21842081

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019997003052A Expired - Lifetime KR100547049B1 (ko) 1996-10-10 1997-10-10 바이러스 감염증 치료를 위한 조성물 및 방법
KR1020057016920A Expired - Lifetime KR100667121B1 (ko) 1996-10-10 1997-10-10 바이러스 감염증 치료를 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020057016920A Expired - Lifetime KR100667121B1 (ko) 1996-10-10 1997-10-10 바이러스 감염증 치료를 위한 조성물 및 방법

Country Status (11)

Country Link
US (6) US6043347A (enExample)
EP (1) EP0939835A4 (enExample)
JP (2) JP2001502315A (enExample)
KR (2) KR100547049B1 (enExample)
CN (1) CN1327896C (enExample)
AU (1) AU732809B2 (enExample)
BR (1) BR9712289A (enExample)
CA (1) CA2268372C (enExample)
MX (1) MXPA02010374A (enExample)
NZ (1) NZ334941A (enExample)
WO (1) WO1998015658A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU732809B2 (en) * 1996-10-10 2001-05-03 Innate Immunotherapeutics Limited Compositions and methods for treating viral infections
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US6599441B1 (en) * 2000-07-18 2003-07-29 Emerald Biostructures, Inc. Crystallization solutions
CN1339319A (zh) * 2000-08-18 2002-03-13 清华大学 一种治疗艾滋病的药物及其制备方法
US6987184B2 (en) * 2001-02-15 2006-01-17 Signal Pharmaceuticals, Llc Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
WO2004091491A2 (en) * 2003-04-10 2004-10-28 Transform Pharmaceuticals, Inc. Profiling conformational variants, antibody compositions and methods of using the same
US7206991B2 (en) * 2003-10-15 2007-04-17 Lsi Logic Corporation Method, apparatus and program for migrating between striped storage and parity striped storage
US7311928B2 (en) * 2003-12-09 2007-12-25 Briant Burke Topical compositions containing tea tree oil for treatment of viral lesions
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
US20060110405A1 (en) * 2004-08-20 2006-05-25 Buckheit Robert W Jr Plasma or serum fraction for treatment and prevention of viral infections and related conditions
US20090130774A1 (en) * 2005-01-13 2009-05-21 David Peretz Elisa assays using prion-specific peptide reagents
EP1855112A1 (en) * 2006-05-10 2007-11-14 Inserm Method for the in vitro screening of compounds inhibiting production of infectious HIV-1 virions
US8200520B2 (en) 2007-10-03 2012-06-12 International Business Machines Corporation Methods, systems, and apparatuses for automated confirmations of meetings
CN103990120B (zh) * 2008-04-01 2018-06-05 伊耐特免疫治疗有限公司 抗感染剂及其用途
EP2271352A4 (en) 2008-04-01 2014-01-15 Innate Therapeutics Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEOPLASTIC DISEASES
NZ571665A (en) * 2008-09-30 2011-01-28 Innate Therapeutics Ltd Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles
WO2010134305A1 (ja) 2009-05-18 2010-11-25 国立大学法人東京医科歯科大学 Ｈｉｖ立体構造認識抗体誘導ペプチド抗原、及びその合成方法
NZ577731A (en) * 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
RU2517084C2 (ru) * 2010-08-06 2014-05-27 Олег Ильич Эпштейн Способ и средство для ингибирования продукции или усиления элиминации белка р24
KR20140027129A (ko) 2011-04-04 2014-03-06 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 Ｈｉｖ 입체 구조 인식 항체 유도 펩티드
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CA3045756A1 (en) * 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Hiv binding agents
CN114605505B9 (zh) * 2018-08-09 2025-04-29 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
US20220267416A1 (en) * 2019-07-15 2022-08-25 Lausanne University Hospital Hiv binding agents
AU2022208435A1 (en) 2021-01-18 2023-08-10 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5528933A (en) * 1978-08-21 1980-02-29 Dai Ichi Seiyaku Co Ltd Muramyldipeptide dimer
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
CA2025634A1 (en) * 1989-09-19 1991-03-20 Thomas Fuerst Peptides including ctl epitopes of hiv proteins and use thereof
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
AU732809B2 (en) * 1996-10-10 2001-05-03 Innate Immunotherapeutics Limited Compositions and methods for treating viral infections

Also Published As

Publication number Publication date
HK1023371A1 (en) 2000-09-08
MXPA02010374A (es) 2003-04-25
KR100667121B1 (ko) 2007-01-12
KR20000048994A (ko) 2000-07-25
WO1998015658A1 (en) 1998-04-16
US6335017B1 (en) 2002-01-01
CN1327896C (zh) 2007-07-25
US8110203B2 (en) 2012-02-07
US20070154917A1 (en) 2007-07-05
US6258599B1 (en) 2001-07-10
JP2009080118A (ja) 2009-04-16
US6670181B2 (en) 2003-12-30
KR20060041157A (ko) 2006-05-11
US20040141996A1 (en) 2004-07-22
AU732809B2 (en) 2001-05-03
EP0939835A4 (en) 2004-10-27
EP0939835A1 (en) 1999-09-08
AU4813197A (en) 1998-05-05
CA2268372A1 (en) 1998-04-16
NZ334941A (en) 2000-11-24
JP2001502315A (ja) 2001-02-20
BR9712289A (pt) 1999-08-31
US20020086034A1 (en) 2002-07-04
US6043347A (en) 2000-03-28
CN1234078A (zh) 1999-11-03
CA2268372C (en) 2012-11-27

Similar Documents

Publication Publication Date Title
KR100667121B1 (ko) 바이러스 감염증 치료를 위한 조성물 및 방법
US5166050A (en) Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
KR920008744B1 (ko) Hiv 감염의 치료 및 진단용 모노클로날항체 및 펩티드
US20030003440A1 (en) Novel CCR5 epitope and antibodies against it
US5128319A (en) Prophylaxis and therapy of acquired immunodeficiency syndrome
JPH06507398A (ja) Ｈｉｖ感染治療のための異種複合抗体
US5834599A (en) Immunoconjugates which neutralize HIV-1 infection
JPH04506004A (ja) Ｈｉｖのｃｄ４結合領域に特異的な抗体
CA1341391C (en) Protective peptides derived from human immunodeficiency virus-1 gp160
JPH05506142A (ja) Ｈｉｖ蛋白質の非免疫支配エピトープに特異的なモノクローナル抗体
AU2006200454B2 (en) Compositions and methods for treating viral infections
US6290963B1 (en) Anti-HIV compositions containing native and recombinant peptides
MXPA99003380A (en) Compositions and methods for treating viral infections
HK1023371B (en) Compositions and methods for treating viral infections
AU2004201322A1 (en) Compositions and methods for treating viral infections
AU2004208648A1 (en) Compositions and methods for treating infections
AU2006200455A1 (en) Compositions and methods for treating viral infections
JP2007534615A (ja) Ｈｉｖ免疫原性複合体
PL161520B1 (pl) Sposób wytwarzania nowego peptydu PL

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19990409

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20021010

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040924

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20050511

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20040924

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20050810

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20050511

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20051020

Appeal identifier: 2005101005241

Request date: 20050810

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20050909

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20050909

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20050810

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20050224

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20051020

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20050920

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20060120

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20060123

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20090109

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20100210

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20101223

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20120119

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20130117

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20130117

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20140120

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20140120

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20150116

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20150116

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20160119

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20160119

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20170119

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20170119

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20180410

Termination category: Expiration of duration